Performance-Based Skills Assessment (UPSA); the Personal and Social Performance (PSP) scale and Specific Level of Functioning (SLOF). We used the Receiver Operating Characteristic (ROC) curves analysis to distinguish between TRS and ARS. Confirmatory logistic regression and discriminant analysis were additionally used. with the exclusion of Area4. A trend toward significance was found for Problem Solving (AUC=.63; p=.08). Among the whole significant variables, the highest specificity for diagnosis was found for NES score and previous hospitalizations (75% and 78.1%, respectively); the highest sensitivity for NES score (71.4%). Accordingly, Odds Ratio of being categorized as TRS were larger for NES score <21.5 (7.5), QLS score <57 (5.49), previous hospitalizations >1.45 and SLOF Area5 <43.5 (4.76 both). Multivariate analysis supported results of ROC curve analysis. Stepwise logistic regression showed that the following variables were significant predictors of TRS/ARS status: previous hospitalizations, NES score, and antipsychotic dose among clinical variables (χ(3)=27.25, p<.0005, Nagelkerke R2=.48); PANSS Negative subscale score among psychopathology variables (χ(1)=7.75, p=.005, Nagelkerke R2=.16); QLS score among quality of life variables (χ(1)=7.91, p=.005, Nagelkerke R2=.16); SLOF Area2 among social functioning variables (χ(1)=18.05, p<.0005, Nagelkerke R2=.34). The descriptive discriminant analysis function was significant for clinical variables, χ(6)=23.84, p=.001. The most relevant discriminator variables in this group were NES score, antipsychotic doses, and previous hospitalizations. Discriminant function was also significant for SLOF variables χ(6)=17.67, p=.007, with Area1 and Area3 scores ensuring the highest discriminative power. Discriminant function was only weakly significant for psychopathology and for quality of life variables (PANSS Negative subscale score and QLS score showed the highest discriminative power, respectively). Discussion: Therefore, the evaluation of a few clinical factors may give solid and predictive information about patient potential to be responsive or non-responsive to antipsychotics. A patient exhibiting a combination of 2 or more lifetime hospitalizations; high NSS; high negative symptoms; low quality of life and psychosocial functioning has low possibility (less than approximately 20%, according to our data) to be responsive to antipsychotic agents.
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Background: Most people with schizophrenia respond robustly to antipsychotic medication but are at very high risk of relapse if these medications are stopped. Long-term maintenance treatment with antipsychotic medication can dramatically reduce the risk of relapse. With long-acting injectable antipsychotic medication (LAI), adherence is documented which may account for superior efficacy in relapse prevention reported in some studies. It is known that plasma antipsychotic levels vary greatly across individuals with standard doses of LAIs. Establishing the lowest effective plasma levels for relapse prevention may also help in minimizing side effects that may contribute to problems with adherence. This study was carried out to describe the plasma paliperidone levels associated with clinical stability in patients receiving the LAI, paliperidone palmitate. We predicted that higher paliperidone plasma levels would be associated with lower subjective well-being and greater levels of sexual dysfunction. Methods: Patients with clinical diagnoses of schizophrenia and schizoaffective disorder attending specialized schizophrenia outpatient clinics at St. Joseph's Healthcare Hamilton were invited to participate if they were receiving maintenance treatment with paliperidone palmitate. The study involved two visits, 3 to 4 weeks apart, on days that subjects were scheduled to receive consecutive injections of paliperidone palmitate. Plasma paliperidone levels and prolactin levels were drawn prior to the injection at Visit 1 and a second paliperidone levels was drawn at Visit 2. At Visit 1, a series of rating scales were also completed including the Subjective Well-being under Neuroleptic scale -Short version (SWN), the Changes in Sexual Functioning Questionnaire (CSFQ) and the Drug Attitude Inventory (DAI). Results: Twenty-one subjects (11F/10M) provided informed consent for this study and had plasma paliperidone levels measured. Patients had been receiving LAI paliperidone for a mean of 18 months (SD = 11.4). Mean paliperidone levels at Visit 1 (n=21) and Visit 2 (n=18) were 34.9 ng/ml (SD = 20.0 ng/ml; range = 5.1-73.9 ng/ml) and 35.1 ng/ml (SD = 17.2 ng/ ml; range = 9.0-67.5 ng/ml), respectively. Plasma paliperidone levels measured at Visit 2 were highly correlated with levels from Visit 1 (n=18; r = .89, p <.001). Plasma prolactin levels were correlated with levels of plasma paliperidone (n=21, r=0.56, p < .01). Lower scores on the CSFQ -Sexual Desire factor were associated with higher levels of paliperidone (n=19, r =-.61, p<.01) and prolactin (n=19, r=-.56, p <.01). Higher paliperidone levels were associated with more negative scores on the Drug Attitude Inventory (n=19, r=-0.49, p < .05). Plasma paliperidone levels were not associated with scores on the SWN (n=21, r=-.-02). Discussion: In patients receiving maintenance treatment with paliperidone palmitate, plasma paliperidone levels varied approximately 15-fold. Higher paliperidone levels were associated with more negative attitudes towards medication and more severe deficits in sexual desire but not with subjective well-being. Many stable patients had plasma level close to the 20ng/ml level which in PET studies leads to 65% dopamine D2 receptor occupancy, a level reported to be associated with antipsychotic response. Our findings raise the possibility that maintaining patients at levels just above the 20ng/ ml level may be sufficient for relapse prevention but may spare the adverse effects such as sexual dysfunction associated with higher plasma levels. These results suggest that measuring plasma levels in patients receiving paliperidone as a LAI may be of value in identifying the minimum effective dose for prevention of relapse and side effects. 1. analyze long-term antipsychotic use and its determinants in Finnish cohort samples, and 2. review the studies on benefits, risks, and follow-up and monitoring practices of long-term antipsychotic treatments.
S230. LONG-TERM ANTIPSYCHOTIC
Methods: 1. We used the data of population-based Northern Finland Birth Cohort 1966 (NFBC1966), and also Finnish therapeutic community data.
